Kynam Capital Management, LP

CIK 0001907884 · PRINCETON, NJ · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source

Kynam Capital Management, LP reported 32 positions worth $1.81B as of June 30, 2026 (13F filed August 14, 2026). Largest holding: CLDX (10.9%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$1.81B
2026 Q2
Positions
32
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
72.7%
Est. Net Flow (Q)
2026 Q2
10 / 32 positions shown
#SymbolCompanyTypeValue% Port.Shares1YYTD
1CLDXCELLDEX THERAPEUTICS INC NEWSH$198.1M10.95%5,322,908
2SNDXSYNDAX PHARMACEUTICALS INCSH$176.0M9.73%8,050,959
3PCVXVAXCYTE INCSH$169.9M9.39%2,922,335
4COGTCOGENT BIOSCIENCES INCSH$141.9M7.84%3,667,097
5VERAVERA THERAPEUTICS INCSH$124.0M6.85%2,890,059
6VRDNVIRIDIAN THERAPEUTICS INCSH$118.6M6.55%6,453,877
7TVTXTRAVERE THERAPEUTICS INCSH$113.6M6.28%2,000,000
8BEAMBEAM THERAPEUTICS INCSH$97.5M5.39%2,840,792
9URGNUROGEN PHARMA LTDSH$89.6M4.95%2,434,207
10LEGNLEGEND BIOTECH CORPSH$86.7M4.79%3,001,205

The free plan shows the top 10 positions. The remaining 22 positions, the full portfolio and quarter changes unlock with Pro.

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Kynam Capital Management, LP hold as of Q2 2026?

Kynam Capital Management, LP reported 32 positions worth $1.81B in its Q2 2026 13F filing. Largest positions: CLDX (10.9%), SNDX (9.7%), PCVX (9.4%), COGT (7.8%) and VERA (6.9%).

What did Kynam Capital Management, LP buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Kynam Capital Management, LP sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.